ATE506456T1 - Verfahren zur behandlung von lentivirusinfektionen - Google Patents

Verfahren zur behandlung von lentivirusinfektionen

Info

Publication number
ATE506456T1
ATE506456T1 AT04776444T AT04776444T ATE506456T1 AT E506456 T1 ATE506456 T1 AT E506456T1 AT 04776444 T AT04776444 T AT 04776444T AT 04776444 T AT04776444 T AT 04776444T AT E506456 T1 ATE506456 T1 AT E506456T1
Authority
AT
Austria
Prior art keywords
present
provides methods
lentivirus infections
treating
identifying
Prior art date
Application number
AT04776444T
Other languages
English (en)
Inventor
Warner Greene
Kimberly Stopak
Noronha Carlos De
Ya-Lin Chiu
Vanessa Soros
Wesley Yonemoto
Original Assignee
David Gladstone Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34068095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE506456(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by David Gladstone Inst filed Critical David Gladstone Inst
Application granted granted Critical
Publication of ATE506456T1 publication Critical patent/ATE506456T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
AT04776444T 2003-06-10 2004-06-09 Verfahren zur behandlung von lentivirusinfektionen ATE506456T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47754903P 2003-06-10 2003-06-10
US50573803P 2003-09-24 2003-09-24
PCT/US2004/018474 WO2005004798A2 (en) 2003-06-10 2004-06-09 Methods for treating lentivirus infections

Publications (1)

Publication Number Publication Date
ATE506456T1 true ATE506456T1 (de) 2011-05-15

Family

ID=34068095

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04776444T ATE506456T1 (de) 2003-06-10 2004-06-09 Verfahren zur behandlung von lentivirusinfektionen

Country Status (8)

Country Link
US (3) US8338180B2 (de)
EP (1) EP1639141B1 (de)
JP (1) JP4653103B2 (de)
AT (1) ATE506456T1 (de)
AU (1) AU2004255564A1 (de)
CA (1) CA2528120A1 (de)
DE (1) DE602004032340D1 (de)
WO (1) WO2005004798A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6831099B1 (en) * 1999-05-12 2004-12-14 Yale University Enzyme inhibition
US20050287648A1 (en) * 2002-08-05 2005-12-29 University Of Rochester Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
US20050112562A1 (en) * 2003-11-10 2005-05-26 Rigel Pharmaceuticals, Inc. Inhibition of retroviral replication through modulation of the host cell ubiquitylation
EP2623113B1 (de) 2005-11-09 2017-05-31 Onyx Therapeutics, Inc. Verbindung zur Enzymhemmung
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
WO2008025564A2 (en) * 2006-08-31 2008-03-06 Nexigen Gmbh Methods for detecting protein-peptide interactions
WO2008136852A2 (en) * 2006-11-01 2008-11-13 University Of Rochester Methods and compositions related to the structure and function of apobec3g
WO2008118871A2 (en) * 2007-03-23 2008-10-02 Rigel Pharmaceuticals, Inc. Methods of detecting inhibitors of vif-mediated apobec3g degradation and hiv
US8067632B2 (en) 2007-07-26 2011-11-29 The Board Of Trustees Of The Leland Stanford Junior University Process to produce prostratin and structural or functional analogs thereof
DK2025750T3 (da) 2007-08-13 2012-02-20 Nexigen Gmbh Targets og forbindelser til terapeutisk intervention af HIV-infektion
CA2701778C (en) 2007-10-04 2018-09-11 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US9084762B2 (en) * 2008-09-30 2015-07-21 The Regents Of The University Of California T-cell immunogens derived from anti-viral proteins and methods of using same
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
CA2653011A1 (en) * 2008-12-03 2010-06-03 Apotex Technologies Inc Method and apparatus for packaging and dispensing pharmaceuticals
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
JP2011115151A (ja) * 2009-11-05 2011-06-16 National Institute Of Advanced Industrial Science & Technology Ａｐｏｂｅｃ３ｇの活性測定方法
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
CA2795559A1 (en) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
US20150272959A1 (en) * 2012-10-04 2015-10-01 Oyagen, Inc. Small molecules as anti-hiv agents that disrupt vif self-association and methods of use thereof
WO2014186423A1 (en) * 2013-05-13 2014-11-20 Oyagen, Inc. Combination therapy for treating hiv and aids
US10588902B2 (en) 2013-06-24 2020-03-17 Oyagen, Inc. Camptothecin derivatives as anti-HIV agents and methods of identifying agents that disrupt Vif self-association
US20180072793A1 (en) * 2015-04-09 2018-03-15 Health Research, Inc. Apobec3a cytidine deaminase induced rna editing
WO2017004151A1 (en) 2015-06-29 2017-01-05 Regents Of The University Of Minnesota Anti-apobec3 antibodies and methods of making and using
EP3433271A4 (de) * 2016-03-23 2019-11-27 Regents of the University of Minnesota Verfahren zum nachweis der apobec3-expression und zur vorhersage klinischer ergebnisse
US11116762B2 (en) 2017-01-04 2021-09-14 Oyagen, Inc. Compounds, compositions, and methods for treating human immunodeficiency virus
GB202110391D0 (en) * 2021-07-19 2021-09-01 Tissue Click Ltd A detection kit and methods of detection of infectious agents
WO2023089808A1 (ja) * 2021-11-22 2023-05-25 隆英 河野 ＡＰＯＢＥＣ３Ｇ／Ｖｉｆ結合体形成阻害剤

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
US5830453A (en) * 1995-05-19 1998-11-03 Emory University Use of IL-13 to induce 15-lipoxygenase
US6051227A (en) * 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5968738A (en) 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
US6020192A (en) 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
TW371617B (en) 1996-10-09 1999-10-11 Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV
AU765703B2 (en) 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US5985577A (en) 1998-10-14 1999-11-16 The Trustees Of Columbia University In The City Of New York Protein conjugates containing multimers of green fluorescent protein
US20030035790A1 (en) * 1999-01-15 2003-02-20 Shu-Hsia Chen Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
WO2002036141A2 (en) 2000-11-02 2002-05-10 Immunex Corporation Method of enhancing lymphocyte-mediated immune responses
US20040009951A1 (en) * 2002-06-13 2004-01-15 Malim Michael H DNA deamination mediates innate immunity to (retro)viral infection
US20050287648A1 (en) * 2002-08-05 2005-12-29 University Of Rochester Protein Transducing Domain/Deaminase Chimeric Proteins, Related Compounds, and Uses Thereof
DE602004012406T2 (de) * 2003-05-23 2009-04-30 Oregon Health & Science University, Portland Verfahren zur identifikation von inhibitoren
CA2537798A1 (en) * 2003-09-03 2005-03-17 University Of Rochester Cytidine deaminase activators, deoxycytidine deaminase activators, vif antagonists, and methods of screening for molecules thereof
US20050112562A1 (en) * 2003-11-10 2005-05-26 Rigel Pharmaceuticals, Inc. Inhibition of retroviral replication through modulation of the host cell ubiquitylation

Also Published As

Publication number Publication date
CA2528120A1 (en) 2005-01-20
US20050053977A1 (en) 2005-03-10
US7723021B2 (en) 2010-05-25
US20070212756A1 (en) 2007-09-13
US20070134653A1 (en) 2007-06-14
WO2005004798A2 (en) 2005-01-20
EP1639141A4 (de) 2007-05-02
WO2005004798A3 (en) 2005-10-20
JP4653103B2 (ja) 2011-03-16
EP1639141B1 (de) 2011-04-20
AU2004255564A1 (en) 2005-01-20
JP2007502624A (ja) 2007-02-15
US8338180B2 (en) 2012-12-25
DE602004032340D1 (de) 2011-06-01
EP1639141A2 (de) 2006-03-29

Similar Documents

Publication Publication Date Title
DE602004032340D1 (de) Verfahren zur behandlung von lentivirusinfektionen
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
ATE411018T1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69915033D1 (de) Verfahren zur keimungshemmende behandlung von knollen und zwiebeln mit eugenol und/oder isoeugenol
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
DE602005019874D1 (de) Für die behandlung von thrombotischen leiden geeignete harnstoffantagonisten des p2y1-rezeptors
ATE490778T1 (de) Verwendung von äd-mealaü3-äetvalü4-ciclosporin zur behandlung von hepatitis-c-infektion
CY1117925T1 (el) Μεθοδος αγωγης και βιοπροσδιορισμος που σχετιζεται με παραγοντα αναστολης της μεταναστευσης των μακροφαγων (mif) ως προερχομενο απο την καρδια μυοκαρδιακο κατασταλτικο παραγοντα
ATE552852T1 (de) Zusammensetzungen und verfahren zur behandlung von virusinfektionen
DE60310400D1 (de) Botulinustoxine zur behandlung von priapismus
EP1595852A4 (de) Verfahren zur behandlung von ammoniakalischen stickstoffenthaltendem wasser
DK1509618T3 (da) Autoimmune sygdomme og NADPH-oxidasedefekter
EP1694342A4 (de) Verfahren zur verwendung von gelsolin zur behandlung oder prävention von bakterieller sepsis
EP1635801A4 (de) Verfahren zur behandlung und prävention von herzarrhythmie
DE602004004883D1 (de) Vegf-antagonisten zur behandlung von diabetes
DE69513027D1 (de) Verfahren zur bestimmung des präthrombotischen status
DE60319753D1 (de) System und verfahren zur dynamisch optimierten nachrichtenverarbeitung
ATE359816T1 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
ATE402120T1 (de) Verfahren und system zur behandlung von wasser
EP1513402A4 (de) Verbesserte inhibitoren von adp-ribosyltransferasen, -cyclasen und -hydrolasen
ATE470453T1 (de) Verfahren zur behandlung von atherosklerose
DE602004010548D1 (de) Verfahren zur behandlung von tierhäuten
DE60325496D1 (de) Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties